Repligen Corporation (RGEN - Free Report) is a leading provider of advanced bioprocessing technologies and solutions used by large biopharmaceutical companies and contract manufacturing organizations for manufacturing biologic drugs, such as monoclonal antibodies (mAbs) and gene therapies.
Repligen earns its revenues from the sale of several products, which can be categorized mainly under four segments, namely filtration, chromatography, protein and process analytics. The company has been progressing well with all its product franchisees performing well during the first nine months of 2020.
Repligen’s earnings surprise record is pretty impressive. It delivered an earnings beat in each of the trailing four quarters, the average being 37.36%. In the last-reported quarter, Repligen delivered an earnings surprise of 42.86%.
Currently, Repligen has a Zacks Rank #2 (Buy). We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Repligen reported earnings of 52 cents per share in the fourth quarter of 2020, which comprehensively beat the Zacks Consensus Estimate of 31 cents.
Revenues: Repligen generated total revenues of $108.6 million during the fourth quarter also beating the Zacks Consensus Estimate of $93.9 million.
Key Stats: Excluding the impact of currency and acquisitions/divestures, Repligen’s revenues grew 47% organically year over year in the fourth quarter of 2020.
2021 Guidance: The company expects total revenues in the range of $500-$525 million for the current year, implying organic growth of 26%-33%. Adjusted EPS is anticipated within $1.86-$1.94 for 2021.
Share Price Impact: Shares were up 6.5% in pre-market trading.
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.
See 8 breakthrough stocks now>>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Repligen Corporation (RGEN - Free Report) is a leading provider of advanced bioprocessing technologies and solutions used by large biopharmaceutical companies and contract manufacturing organizations for manufacturing biologic drugs, such as monoclonal antibodies (mAbs) and gene therapies.
Repligen earns its revenues from the sale of several products, which can be categorized mainly under four segments, namely filtration, chromatography, protein and process analytics. The company has been progressing well with all its product franchisees performing well during the first nine months of 2020.
Repligen’s earnings surprise record is pretty impressive. It delivered an earnings beat in each of the trailing four quarters, the average being 37.36%. In the last-reported quarter, Repligen delivered an earnings surprise of 42.86%.
Currently, Repligen has a Zacks Rank #2 (Buy). We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Repligen reported earnings of 52 cents per share in the fourth quarter of 2020, which comprehensively beat the Zacks Consensus Estimate of 31 cents.
Revenues: Repligen generated total revenues of $108.6 million during the fourth quarter also beating the Zacks Consensus Estimate of $93.9 million.
Key Stats: Excluding the impact of currency and acquisitions/divestures, Repligen’s revenues grew 47% organically year over year in the fourth quarter of 2020.
2021 Guidance: The company expects total revenues in the range of $500-$525 million for the current year, implying organic growth of 26%-33%. Adjusted EPS is anticipated within $1.86-$1.94 for 2021.
Share Price Impact: Shares were up 6.5% in pre-market trading.
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.
See 8 breakthrough stocks now>>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on RGEN - FREE